Steroid-naive UV patients can finally have a relief

According to a research article published in the World Journal of Gastroenterology that came after investigations were concluded by Dr. Masatoshi Kudo from Kinki University School of Medicine of Japan, the therapeutic utility of LCAP (Leukocytapheresis) for steroid-naïve patient can now be handled in a better way as efficacy of LCAP can now be predicted on the basis of endoscopic findings.

Despite the fact that steroid administration is hailed as a second-line therapy for inducing remission in UC if remissions are not attainable by salazosulfapyridine or mesalazine treatment, it was revealed that steroid administration can result in different side effects.

From Eurekalert.org:

In 1995, LCAP was introduced for patients with UC. LCAP is a method where the blood is passed though a leukocyte removal filter before being returned to the body. On average, 1.6 × 1010 leukocytes are removed during one session. These leukocytes include granulocytes, lymphocytes and monocytes. Almost 100% of granulocytes and monocytes and 60% of lymphocytes are removed by removal filter. In this study, we found 61.1% of steroid-naive UC patients (11/18) had entered remission eight weeks after the last LCAP session.

Since steroids can induce remission in 45% to 90% of salazosulfapyridine or mesalazine non-responders, it appears that LCAP is as efficacious as steroids as a second-line treatment. Analysis of the endoscopic findings of the patients revealed that while the remission rate of the patients with erosion was extremely high after LCAP; however, that of the patients with geographic ulcers and deep ulcers extremely low. None of the patients experienced any severe adverse effects from LCAP. Given the low rate of adverse events suffered by patients treated with LCAP, we propose that patients with moderately active UC should be treated with LCAP before steroids are considered.

The study went on to reveal that LCAP can an efficacious treatment option for steroid-naive UC patients with moderate activity and endoscopic revelations can be used to predict treatment efficacy.